Algen Biotechnologies utilizes a proprietary CRISPR gene-modulation system and advanced AI models to decode complex gene networks and identify disease-driving RNA signaling pathways. This approach accelerates therapeutic drug discovery by providing high-confidence insights into the biological mechanisms underlying various diseases.

Bolden Therapeutics is developing first-in-class antisense oligonucleotides to enhance neurogenesis, targeting a specific molecular pathway to promote the formation of new neurons in the adult brain. This approach aims to address cognitive dysfunction associated with neurodegenerative diseases such as Alzheimer's and ischemic stroke.

Deciduous Therapeutics develops immune modulatory therapies that activate the body's natural immune mechanisms to eliminate senescent cells, which contribute to age-related diseases. By targeting these dysfunctional cells, the company aims to improve health span and mitigate the effects of inflammation and tissue remodeling associated with aging.

Fauna Bio utilizes an AI-driven platform, Convergence™, to analyze genetic data from diverse mammalian species, enabling the discovery of novel therapeutic targets for age-related diseases and metabolic disorders. By replicating the natural disease resistance mechanisms found in these animals, the company aims to develop effective drugs that can improve human health outcomes.

Immunis is a biotechnology company developing IMM01-STEM, a biologic therapy that utilizes natural human immune modulators to enhance muscle regeneration and metabolism. The company is conducting a Phase 1/2a clinical trial to evaluate the therapy's effectiveness in treating age-related muscle atrophy.

This company develops small molecule therapeutics aimed at treating age-related diseases by engineering aging medicine. They utilize an integrated platform combining optogenetics, chemistry, and AI to unravel complex biology with high precision. This approach allows for the systematic exploration of chemical space to unlock novel therapeutic opportunities.

LIfT Biosciences develops Immuno-Modulatory Alpha Neutrophils (IMANs), a first-in-class allogeneic innate cell therapy designed to directly kill cancer cells while enhancing the immune system's ability to identify and eliminate tumors. This dual mechanism addresses the challenge of insufficient immune response in cancer treatment, aiming to improve patient outcomes in oncology.

Provides a fully digital property management platform for long-term rental owners, handling tenant placement, maintenance, rent collection, and financial reporting through a centralized app. Reduces the time and effort required for property management by offering 24/7 support, self-guided tours, and automated lease generation for a flat fee of $65 per unit per month.

Matter Bio is a longevity holding company focused on preserving genome integrity by addressing mutations, structural variations, and epigenetic drift that accumulate with age. The company employs a team of scientists to develop targeted interventions that counteract genomic information loss, aiming to slow and potentially reverse key drivers of aging.

Modulo Bio develops therapeutics that target microglial cells to treat neurological conditions. Their technology identifies specific microglial behaviors that support and restore brain health by analyzing common signals across various neuroimmune system models. The company focuses on creating drugs that enhance the neuroimmune system for therapeutic intervention.

The startup has developed a nanomedical platform that utilizes targeted nanoparticles to selectively remove disease-causing molecules from the bloodstream within minutes. This technology provides a new treatment option for major diseases, enhancing patient safety and efficacy compared to traditional methods.

This clinical-stage biotechnology firm develops preventative and regenerative therapies for type 1 and type 2 diabetes. The company focuses on preventing disease progression and restoring pancreatic function.

PriveBio develops precision therapeutics targeting metabolic dysfunction and fibro-inflammation in cardiorenal diseases, including obesity and chronic kidney disease, by utilizing human proteo-genomics data from extensive datasets. The company focuses on validated therapeutic targets to improve patient outcomes in these complex conditions.

Rejuvenate Bio utilizes gene therapy to develop treatments aimed at reversing aging and addressing chronic, age-related diseases that affect six in ten Americans. By targeting the underlying genetic factors of these conditions, the company aims to reduce the prevalence and healthcare costs associated with chronic diseases.

Rejuvenation Technologies utilizes nucleoside-modified TERT mRNA to temporarily activate telomerase, enabling the safe extension of telomeres in human cells. This approach addresses the critical shortening of telomeres, which contributes to cellular aging and various age-related diseases, by potentially reversing the effects of aging at the chromosomal level.

Remedium Bio has developed the Prometheus™ adjustable gene therapy platform, which enables the localized delivery of therapeutic genes through a single subcutaneous injection, allowing for precise post-treatment dose adjustments. The company addresses significant clinical needs by providing durable alternatives to protein-based therapies for conditions such as obesity, type 2 diabetes, and osteoarthritis, potentially reducing treatment costs and improving patient outcomes.

Senisca develops RNA senotherapeutics that target dysregulated RNA splicing, a newly identified hallmark of aging that contributes to cellular senescence and age-related diseases. By restoring splicing factor levels in senescent cells, Senisca aims to reverse the detrimental effects of aging on cellular health and improve tissue function.